TherOx^® has developed a proprietary medical technology called SuperSaturated Oxygen (SSO₂) Therapy. SSO₂ Therapy creates a highly oxygenated saline solution and combines it with the patient’s arterial blood to provide focal hyperoxemic oxygen therapy to ischemic (oxygen-deprived) tissue. The focus of SSO₂ Therapy is for the treatment of acute myocardial infarction (heart attack).

SSO₂ Therapy complements percutaneous coronary intervention (PCI) and is designed to minimize myocardial damage caused by acute myocardial infarction in qualifying patients suffering a LAD STEMI event who are treated with primary PCI within 6 hours of symptom onset. SSO₂ Therapy delivers superoxygenated arterial blood directly to at-risk myocardial tissue, increasing oxygen diffusion to the ischemic zone, resulting in restored microvascular flow (shown in preclinical studies) [Fig. 1]. SSO₂ has been shown in an FDA-sanctioned trial to reduce infarct size by 26%.¹

Figure 1.

¹ Stone, et al. Circ Cardiovasc Interv. 2009 Oct; 2:366-375. Subset data on file at TherOx, Inc.

_{Caution: Federal (United States) law restricts this device to sale by or on the order of a physician. The TherOx SSO2 System is indicated for the preparation and delivery of SuperSaturated Oxygen Therapy (SSO2 Therapy) to targeted ischemic regions perfused by the patient’s left anterior descending coronary artery immediately following revascularization by means of percutaneous coronary intervention (PCI) with stenting that has been completed within 6 hours after the onset of anterior acute myocardial infarction (AMI) symptoms caused by a left anterior descending artery infarct lesion.}

_{Indications For Use: The TherOx DownStream System is indicated for the preparation and delivery of SuperSaturated Oxygen Therapy (SSO2 Therapy) to targeted ischemic regions perfused by the patient’s left anterior descending coronary artery immediately following revascularization by means of percutaneous coronary intervention (PCI) with stenting that has been completed within 6 hours after the onset of anterior acute myocardial infarction (AMI) symptoms caused by a left anterior descending artery infarct lesion.}